Medicus Pharma Regains Nasdaq Shareholders' Equity Compliance

The Nasdaq Capital Market listing requirement was met after roughly $4.25 million in equity financings and a debt-to-preferred exchange.

Updated on Nov. 19, 2026 in Public Companies

Medicus Pharma Regains Nasdaq Shareholders' Equity Compliance

Nasdaq has notified Medicus Pharma Ltd. that it regained compliance with the $2.5 million minimum shareholders' equity requirement for continued listing on The Nasdaq Capital Market. The determination was based on transactions described in a Form 8-K filed with the SEC on November 16, 2026.

Why it matters

Regaining compliance keeps Medicus Pharma's shares listed on the Nasdaq Capital Market, but the status is conditional on the company showing continued compliance in its next periodic report. Failure to do so could expose the company to delisting.

The company completed about $4.25 million in equity financings, including a $3.0 million registered direct offering and roughly $1.25 million in insider-led private placements, against Nasdaq's $2.5 million minimum shareholders' equity requirement. Medicus also exchanged $10.5 million of indebtedness held by Streeterville Capital, LLC for non-convertible preferred shares, and it is not yet clear whether equity will hold above the threshold in the December 31, 2026 report.

The players

Medicus Pharma Ltd.

A Philadelphia-headquartered pharmaceutical company whose shares trade on The Nasdaq Capital Market.

Nasdaq

The U.S. stock exchange operator that set the shareholders' equity listing requirement and issued the compliance notice.

Dr. Raza Bokhari

An executive of Medicus Pharma who invested $750,000 through a controlled entity in the company's private placements.

The details

Nasdaq sent Medicus Pharma a Conditional Compliance Notice on November 18, 2026, confirming the company regained compliance with Listing Rule 5550(b)(1). The company's equity was boosted by private placements led by insiders, including a $750,000 investment by Dr. Raza Bokhari through a controlled entity, and by the exchange of $10.5 million in debt for preferred shares.

Timeline

  1. November 16, 2026: Medicus Pharma filed a Form 8-K with the SEC detailing the transactions.

  2. November 18, 2026: Nasdaq issued the Conditional Compliance Notice.

  3. November 19, 2026: Medicus announced it had regained Nasdaq compliance.

  4. December 31, 2026: End of the period covered by the company's next periodic report, which must show continued compliance.

Market Landscape

Nasdaq Listing Rule 5550(b)(1) sets a $2.5 million shareholders' equity floor for Capital Market companies, and Medicus Pharma's cure relied on the same tools many small-cap issuers use: registered offerings, insider-led placements and debt-for-preferred swaps. The outcome remains conditional, leaving the company's listing tied to its next periodic filing.

For investors holding Medicus Pharma shares, the listing remains in place for now but depends on the company's next periodic report showing equity above the $2.5 million threshold. Shareholders should watch that filing, since a shortfall could lead to delisting and reduced liquidity.

The takeaway

Regaining listing compliance is only the first step; companies must sustain the required equity level in subsequent filings. Investors should track the December 31, 2026 periodic report to see whether the cure holds.

What happens next

Medicus Pharma's next periodic report for the period ending December 31, 2026 must evidence continued compliance with the minimum shareholders' equity requirement, or the company may face delisting.

Further reading

For more on how listed companies manage exchange requirements, explore Public Companies coverage.

Source note: This article includes information reported by The Manila times.